Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: BIIB147 in Amyotrophic Lateral Sclerosis
NCT07855211Phase 2Recruiting
- Sponsor
- Biogen
- Start
- Oct 2026
- Primary completion
- Jan 2034
- Countries
- 1
01
Overview
A Phase 2 trial of BIIB147 in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Started Oct 2026; status: recruiting.
02
Drugs
BIIB147
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07855211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855211.